7 Aptamers for Personalized Therapeutics
205
105. Raschi E, De Ponti F (2012) Cardiovascular toxicity of anticancer-targeted therapy: emerging
issues in the era of cardio-oncology. Intern Emerg Med 7(2):113–131
106. Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem
Res 41(1):98–107
107. Zhang Y, Prakash DR, Zhang H (2019) Nucleotide aptamers as theranostic biomaterials. In:
Theranostic bionanomaterials. Elsevier, pp 423–446
108. Zhu G, Niu G, Chen X (2015) Aptamer–drug conjugates. Bioconjugate Chem 26(11):2186–
2197
109. Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, Chen Y, Tan W (2009) Molecular assembly of an aptamer–drug conjugate for targeted drug delivery to tumor cells.
ChemBioChem 10(5):862–868
110. Zhang Z, Ali MM, Eckert MA, Kang D-K, Chen YY, Sender LS, Fruman DA, Zhao W (2013)
A polyvalent aptamer system for targeted drug delivery. Biomaterials 34(37):9728–9735
111. Baek SE, Lee KH, Park YS, Oh D-K, Oh S, Kim K-S, Kim D-E (2014) RNA aptamerconjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells
in vivo. J Control Release 196:234–242
112. Li L, Hou J, Liu X, Guo Y, Wu Y, Zhang L, Yang Z (2014) Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant
melanomas. Biomaterials 35(12):3840–3850
113. Li X, Wu X, Yang H, Li L, Ye Z, Rao Y (2019) A nuclear targeted Dox-Aptamer loaded
liposome delivery platform for the circumvention of drug resistance in breast cancer. Biomed
Pharmacother 117:109072
114. Wu X, Chen J, Wu M, Zhao JX (2015) Aptamers: active targeting ligands for cancer diagnosis
and therapy. Theranostics 5(4):322
115. Lee JH, Yigit MV, Mazumdar D, Lu Y (2010) Molecular diagnostic and drug delivery agents
based on aptamer-nanomaterial conjugates. Adv Drug Deliv Rev 62(6):592–605
116. Li N, Nguyen HH, Byrom M, Ellington AD (2011) Inhibition of cell proliferation by an
anti-EGFR aptamer. PloS one 6(6)
117. Aravind A, Yoshida Y, Maekawa T, Kumar DS (2012) Aptamer-conjugated polymeric
nanoparticles for targeted cancer therapy. Drug Deliv Transl Res 2(6):418–436
118. Matsumura S, Ajima K, Yudasaka M, Iijima S, Shiba K (2007) Dispersion of cisplatin-loaded
carbon nanohorns with a conjugate comprised of an artificial peptide aptamer and polyethylene
glycol. Mol Pharm 4(5):723–729
119. Aryal S, Hu C-MJ, Zhang L (2010) Polymer−cisplatin conjugate nanoparticles for acidresponsive drug delivery. ACS Nano 4(1):251–258
120. Zhou J, Rossi JJ (2014) Cell-type-specific, aptamer-functionalized agents for targeted disease
therapy. Mol Ther Nucl Acids 3:e169
121. Jing P, Cao S, Xiao S, Zhang X, Ke S, Ke F, Yu X, Wang L, Wang S, Luo Y (2016) Enhanced
growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated
dual-aptamer modified drug delivery system. Cancer Lett 383(2):230–242
122. Alibolandi M, Ramezani M, Sadeghi F, Abnous K, Hadizadeh F (2015) Epithelial cell adhesion molecule aptamer conjugated PEG–PLGA nanopolymersomes for targeted delivery of
doxorubicin to human breast adenocarcinoma cell line in vitro. Int J Pharm 479(1):241–251
123. Yu MK, Kim D, Lee IH, So JS, Jeong YY, Jon S (2011) Image-guided prostate cancer
therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide
nanoparticles. Small 7(15):2241–2249
124. Lin H-C, Li W-T, Madanayake TW, Tao C, Niu Q, Yan S-Q, Gao B-A, Ping Z (2020) Aptamerguided upconversion nanoplatform for targeted drug delivery and near-infrared light-triggered
photodynamic therapy. J Biomater Appl 0885328219882152
125. Sullenger B, Gray B, Nichols M (2020) Antidote-mediated reversal of extracellular aptamer
staining. Google Patents
126. Gray BP, Requena MD, Nichols MD, Sullenger BA (2020) Aptamers as reversible sorting
ligands for preparation of cells in their native state. Cell Chem Biol 27(2):232–244 (e237)
205
105. Raschi E, De Ponti F (2012) Cardiovascular toxicity of anticancer-targeted therapy: emerging
issues in the era of cardio-oncology. Intern Emerg Med 7(2):113–131
106. Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem
Res 41(1):98–107
107. Zhang Y, Prakash DR, Zhang H (2019) Nucleotide aptamers as theranostic biomaterials. In:
Theranostic bionanomaterials. Elsevier, pp 423–446
108. Zhu G, Niu G, Chen X (2015) Aptamer–drug conjugates. Bioconjugate Chem 26(11):2186–
2197
109. Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, Chen Y, Tan W (2009) Molecular assembly of an aptamer–drug conjugate for targeted drug delivery to tumor cells.
ChemBioChem 10(5):862–868
110. Zhang Z, Ali MM, Eckert MA, Kang D-K, Chen YY, Sender LS, Fruman DA, Zhao W (2013)
A polyvalent aptamer system for targeted drug delivery. Biomaterials 34(37):9728–9735
111. Baek SE, Lee KH, Park YS, Oh D-K, Oh S, Kim K-S, Kim D-E (2014) RNA aptamerconjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells
in vivo. J Control Release 196:234–242
112. Li L, Hou J, Liu X, Guo Y, Wu Y, Zhang L, Yang Z (2014) Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant
melanomas. Biomaterials 35(12):3840–3850
113. Li X, Wu X, Yang H, Li L, Ye Z, Rao Y (2019) A nuclear targeted Dox-Aptamer loaded
liposome delivery platform for the circumvention of drug resistance in breast cancer. Biomed
Pharmacother 117:109072
114. Wu X, Chen J, Wu M, Zhao JX (2015) Aptamers: active targeting ligands for cancer diagnosis
and therapy. Theranostics 5(4):322
115. Lee JH, Yigit MV, Mazumdar D, Lu Y (2010) Molecular diagnostic and drug delivery agents
based on aptamer-nanomaterial conjugates. Adv Drug Deliv Rev 62(6):592–605
116. Li N, Nguyen HH, Byrom M, Ellington AD (2011) Inhibition of cell proliferation by an
anti-EGFR aptamer. PloS one 6(6)
117. Aravind A, Yoshida Y, Maekawa T, Kumar DS (2012) Aptamer-conjugated polymeric
nanoparticles for targeted cancer therapy. Drug Deliv Transl Res 2(6):418–436
118. Matsumura S, Ajima K, Yudasaka M, Iijima S, Shiba K (2007) Dispersion of cisplatin-loaded
carbon nanohorns with a conjugate comprised of an artificial peptide aptamer and polyethylene
glycol. Mol Pharm 4(5):723–729
119. Aryal S, Hu C-MJ, Zhang L (2010) Polymer−cisplatin conjugate nanoparticles for acidresponsive drug delivery. ACS Nano 4(1):251–258
120. Zhou J, Rossi JJ (2014) Cell-type-specific, aptamer-functionalized agents for targeted disease
therapy. Mol Ther Nucl Acids 3:e169
121. Jing P, Cao S, Xiao S, Zhang X, Ke S, Ke F, Yu X, Wang L, Wang S, Luo Y (2016) Enhanced
growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated
dual-aptamer modified drug delivery system. Cancer Lett 383(2):230–242
122. Alibolandi M, Ramezani M, Sadeghi F, Abnous K, Hadizadeh F (2015) Epithelial cell adhesion molecule aptamer conjugated PEG–PLGA nanopolymersomes for targeted delivery of
doxorubicin to human breast adenocarcinoma cell line in vitro. Int J Pharm 479(1):241–251
123. Yu MK, Kim D, Lee IH, So JS, Jeong YY, Jon S (2011) Image-guided prostate cancer
therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide
nanoparticles. Small 7(15):2241–2249
124. Lin H-C, Li W-T, Madanayake TW, Tao C, Niu Q, Yan S-Q, Gao B-A, Ping Z (2020) Aptamerguided upconversion nanoplatform for targeted drug delivery and near-infrared light-triggered
photodynamic therapy. J Biomater Appl 0885328219882152
125. Sullenger B, Gray B, Nichols M (2020) Antidote-mediated reversal of extracellular aptamer
staining. Google Patents
126. Gray BP, Requena MD, Nichols MD, Sullenger BA (2020) Aptamers as reversible sorting
ligands for preparation of cells in their native state. Cell Chem Biol 27(2):232–244 (e237)